Chronic Inflammatory Demyelinating Polyneuropathy

Neurology·MeSH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Prevalence

5.0 / 100K

18 drugs in development·6 companies·9 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
cutaquig	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
cuvitru	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
gammagard liquid	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hizentra	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hyqvia	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
xembify	KORU Medical Systems Inc. Common Stock (DE) (KRMD)

Phase 3(9)

Drug	Company
Batoclimab	Immunovant, Inc. (IMVT)
claseprubart	Dianthus Therapeutics, Inc. /DE/ (DNTH)
Empasiprubart	ARGENX SE (ARGX)
Empasiprubart IV	ARGENX SE (ARGX)
ivig	Sanofi (SNY)
IVIg	Sanofi (SNY)
IVIG	ARGENX SE (ARGX)
riliprubart	Sanofi (SNY)
riliprubart	Sanofi (SNY)

Phase 2(1)

Drug	Company
imeroprubart	Immunovant, Inc. (IMVT)

Phase 2/Phase 3(1)

Drug	Company
imvt-1402	Roivant Sciences Ltd. (ROIV)

Phase 4(1)

Drug	Company
Efgartigimod PH20 SC	ARGENX SE (ARGX)

BioSniper tracks 18 drugs in development for Chronic Inflammatory Demyelinating Polyneuropathy across 6 companies.

There are 9 clinical trials targeting Chronic Inflammatory Demyelinating Polyneuropathy tracked by BioSniper.

The estimated prevalence of Chronic Inflammatory Demyelinating Polyneuropathy is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.